Danaher Corporation $DHR Stake Increased by Cohen Klingenstein LLC

Key Points

• Cohen Klingenstein LLC increased its Danaher stake by 227.1% in the third quarter, reaching 31,400 shares valued at approximately $6.96 million. Institutional investors collectively own 79.05% of Danaher.
• Danaher reported quarterly results above expectations, with adjusted earnings of $1.94 per share and revenue of $6.26 billion, up 5.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $235.41.
• Danaher and NVIDIA are collaborating on AI-enabled autonomous science, while Danaher plans to launch its first commercial-scale AI-powered autonomous laboratory in early 2027.

Cohen Klingenstein LLC grew its holdings in Danaher Corporation (NYSE:DHR - Free Report) by 227.1% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 31,400 shares of the conglomerate's stock after buying an additional 21,800 shares during the quarter. Cohen Klingenstein LLC's holdings in Danaher were worth $6,957,000 at the end of the most recent reporting period.

Other institutional investors have also made changes to their positions in the company. BlackRock Inc. bought a new stake in Danaher during the 2nd quarter worth about $10,492,520,000. Wellington Management Group LLP raised its stake in shares of Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate's stock worth $3,108,031,000 after acquiring an additional 1,542,310 shares during the last quarter. Jupiter Topco LLC bought a new position in shares of Danaher in the second quarter worth about $1,456,317,000. Generation Investment Management LLP bought a new position in shares of Danaher in the second quarter worth about $1,287,949,000. Finally, Bank of America Corp DE acquired a new position in shares of Danaher during the second quarter worth approximately $993,846,000. 79.05% of the stock is owned by institutional investors.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher and NVIDIA announced an AI collaboration to combine Danaher’s scientific instruments, laboratory workflows, automation technology and software with NVIDIA’s accelerated computing and AI capabilities. The partnership is intended to advance autonomous science and speed drug discovery and other laboratory research. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Danaher is also preparing to launch its first AI-powered autonomous laboratory, targeted to operate at commercial scale in early 2027. The initiative could support longer-term growth in laboratory automation and strengthen the company’s position in AI-enabled life-science research. How to Invest in AI Drug Discovery
• Positive Sentiment: Multiple Zacks reports say Danaher has a favorable combination of earnings-estimate trends and Earnings ESP, suggesting potential for the company to exceed consensus estimates in its next quarterly report. Danaher has also recently demonstrated earnings momentum, with its latest reported quarter exceeding both EPS and revenue expectations. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Neutral Sentiment: Danaher is projected to announce earnings on Wednesday. Investors will be watching revenue growth, management’s outlook and whether diagnostics and life-sciences demand support the anticipated improvement in earnings. Danaher Projected to Announce Earnings

Danaher Stock Up 3.0%

Shares of NYSE:DHR opened at $231.52 on Friday. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The company has a 50 day moving average of $213.55 and a 200-day moving average of $195.74. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The stock has a market cap of $162.76 billion, a price-to-earnings ratio of 41.12, a P/E/G ratio of 2.82 and a beta of 0.76.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business had revenue of $6.26 billion for the quarter, compared to analyst estimates of $6.12 billion. During the same period in the prior year, the business posted $0.77 earnings per share. Danaher's revenue was up 5.5% compared to the same quarter last year. On average, sell-side analysts forecast that Danaher Corporation will post 8.53 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher's payout ratio is currently 28.42%.

Wall Street Analysts Forecast Growth

DHR has been the topic of several research analyst reports. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a $240.00 price target on shares of Danaher in a research note on Wednesday, July 22nd. Guggenheim boosted their price objective on shares of Danaher from $200.00 to $250.00 and gave the stock a "buy" rating in a research report on Thursday, October 1st. UBS Group began coverage on shares of Danaher in a research report on Wednesday, September 9th. They issued a "buy" rating and a $250.00 price objective for the company. Wells Fargo & Company reduced their price objective on Danaher from $212.00 to $195.00 and set an "equal weight" rating on the stock in a report on Wednesday, July 22nd. Finally, Evercore reiterated an "outperform" rating and issued a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $235.41.

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.